ACOG hosts Annual Clinical & Scientific Meeting live for first time in 3 years
Click Here to Manage Email Alerts
After 2 consecutive years of virtual conferences, ACOG is back to hosting its Annual Clinical & Scientific Meeting in person.
“The ACOG Annual Clinical & Scientific Meeting is unique in that it serves as a benchmark for the technological, scientific and clinical progress that OB/GYNs have made in the past year and allows attendees to return to their practice refreshed, reenergized and ready to continue innovating on behalf of their patients and their specialty,” J. Martin Tucker, MD, FACOG, president of ACOG, told Healio.
Although some presentations at this year’s fully in-person meeting — held May 6-8 in San Diego — will focus on the impact of COVID-19 on both physicians and patients, many will touch upon other recent findings and current issues related to obstetrics and gynecology.
“We’ll also be hearing from some of the field’s brightest minds on a lot of timely topics, such as reproductive health care and how legislation affects access to these critical resources; racial equity in health care; and the latest innovations and advances in knowledge and technology in obstetrics and gynecology,” Tucker said.
Given that this is the first time since May 2019 that the annual meeting is being held in person, Tucker expressed his eagerness to reconnect with colleagues and friends.
“As an annual meeting attendee myself, I can say we are all looking forward to gathering in person and being reminded of the strength, innovation and dedication to our patients and our specialty that makes up the foundation of the OB/GYN community,” he said.
To get ready for this year’s meeting, here is a look back at some of the top stories from last year’s meeting.
CBD cocktail as effective as ibuprofen in reducing menstrual pain
Flow Formula, a botanical blend containing CBD, was as effective as ibuprofen in relieving menstrual pain symptoms, according to results of a randomized, placebo-controlled, double-blinded trial. Read more.
Nearly 40% of women change breastfeeding plans because of childbirth experiences
Almost four in 10 women had a childbirth experience, such as pain from a cesarean delivery, that made them change their breastfeeding plans, survey data showed. Read more.
Novel antifungal effective against vulvovaginal candidiasis in phase 3 trials
Ibrexafungerp was superior to placebo in patients with vulvovaginal candidiasis, with statistically significant rates of clinical cure, clinical improvement and mycological eradication, according to results of the phase 3 VANISH-306 trial. Read more.
Tdap information on social media, professional sites often incorrect or incomplete
Information on the Tdap vaccine was often incomplete on professional websites and incorrect on social media, particularly Facebook and Instagram, according to researchers. Read more.
Novel copper IUD proves safe, effective during first year of phase 3 trial
A copper intrauterine device, or IUD, with a novel design was safe, effective and well-tolerated in women during the first year of use, according to results from a phase 3 clinical trial. Read more.